Pharmacological neuroenhancement and brain doping: Chances and risks;Pharmakologisches neuroenhancement und "hirndoping": Chancen und risiken

Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz

Volumn 53, Issue 8, 2010, Pages 853-860

  Franke, A G ^a   Lieb, K ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Brain doping; Cognitive; Enhancement; Neuroenhancement; Psychostimulants

Indexed keywords

BENZHYDRYL DERIVATIVE; CENTRAL STIMULANT AGENT; MODAFINIL; PSYCHOTROPIC AGENT;

ADDICTION; ARTICLE; BRAIN; CROSS-SECTIONAL STUDY; DOSE RESPONSE; DRUG EFFECT; GERMANY; HUMAN; MENTAL FUNCTION; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL (TOPIC);

BENZHYDRYL COMPOUNDS; BRAIN; CENTRAL NERVOUS SYSTEM STIMULANTS; CROSS-SECTIONAL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; GERMANY; HUMANS; MENTAL PROCESSES; PSYCHOTROPIC DRUGS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SUBSTANCE-RELATED DISORDERS;

EID: 77956110346     PISSN: 14369990     EISSN: 14371588     Source Type: Journal    
DOI: 10.1007/s00103-010-1105-0     Document Type: Article

References (43)

1. Lieb K (2010) Hirndoping - Warum wir nicht alles schlucken sollten. Artemis und Winkler, Düsseldorf (im Druck)
2. Baron DA, Martin DM, Abol MS (2007) Doping in sports and its spread to at-risk populations: an international review. World Psychiatry 6:118-123
3. Teter CJ, McCabe SE, Cranford JA et al (2005) Prevalence and motives for illicit use of prescription stimulants in an undergraduate student sample. J Am Coll Health 53:253-262
4. Deutsche Angestelltenkrankenkasse (DAK) (2009) Gesundheitsreport 2009. Analyse der Arbeitsunfähigkeitsdaten. Schwerpunktthema Doping am Arbeitsplatz. Eigenverlag, Berlin Hamburg
5. Franke AG, Bonertz C, Christmann M et al (2009) Use of potential neurocognitive enhancing substances and attitudes towards them among pupils in Germany. Brain Matters, Sept. 24.-26., 2009, Halifax, Nova Scotia, Canada
6. Maher B (2008) Poll results: look who's doping. Nature 452:674-675
7. Wilens TE (2008) Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 28:S46-S53
8. Prince J (2008) Catecholamine dysfunction in attention-deficit/ hyperactivity disorder: an update. J Clin Psychopharmacol 28:S 39-45
9. Oades RD, Sadile AG, Sagvolden T et al (2005) The control of responsiveness in ADHD by catecholamines: evidence for dopaminergic, noradrenergic and interactive roles. Dev Sci 8:122-131
10. Bukstein O (2008) Substance abuse in patients with attention-deficit/ hyperactivity disorder. Medscape J Med 10:24
11. Kollins SH (2008) A qualitative review of issues arising in the use of psycho-stimulant medications in patients with ADHD and co-morbid substance use disorders. Curr Med Res Opin 24:1345-1357
12. Wilens TE (2007) The nature of the relationship between attention-deficit/hyperactivity disorder and substance use. J Clin Psychiatry 68(Suppl 11):4-8
13. Barkley RA, Fischer M, Smallish L, Fletcher K (2003) Does the treatment of attention-deficit/hyperactivity disorder with stimulants contribute to drug use/abuse? A 13-year prospective study. Pediatrics 111:97-109
14. Biederman J, Monuteaux MC, Spencer T et al (2008) Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study. Am J Psychiatry 165:597-603
15. Bright GM (2008) Abuse of medications employed for the treatment of ADHD: results from a large-scale community survey. Medscape J Med 10:111
16. U.S. Food and Drug Administration (FDA) Sicherheitshinweis am 29.5.2005: Public health advisory suicidal thinking in children and adolescents being treated with strattera (Atomoxetine). Rockville, Maryland
17. Gould MS, Walsh BT, Munfakh JL et al (2009) Sudden death and use of stimulant medications in youths. Am J Psychiatry 166:992-1001
18. Rugino TA, Samsock TC (2003) Modafinil in children with attention-deficit hyperactivity disorder. Pediatr Neurol 29:136-142
19. Minzenberg MJ, Carter CS (2008) Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology 33:1477-1502
20. Wesensten NJ, Killgore WD, Balkin TJ (2005) Performance and alertness effects of caffeine, dextroamphetamine, and modafinil during sleep deprivation. J Sleep Res 14:255-266
21. Killgore WD, Kahn-Greene ET, Grugle NL et al (2009) Sustaining executive functions during sleep deprivation: a comparison of caffeine, dextroamphetamine, and modafinil. Sleep 32:205-216
22. Rugino T (2007) A review of modafinil film-coated tablets for attention-deficit/hyperactivity disorder in children and adolescents. Neuropsychiatr Dis Treat 3:293-301
23. Franke AG, Lieb K, Fellgiebel A (2009) From symptomatic to disease modifying therapy? Recent developments in the pharmacotherapy of Alzheimer's disease. Fortschr Neurol Psychiatr 77:326-333
24. Nehlig A, Daval JL, Debry G (1992) Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects. Brain Res Brain Res Rev 17:139-170
25. Ferre S, Ciruela F, Borycz J et al (2008) Adenosine A1-A2A receptor heteromers: new targets for caffeine in the brain. Front Biosci 13:2391-2399
26. Fisone G, Borgkvist A, Usiello A (2004) Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci 61:857-872
27. Marley E, Nistico G (1972) Effects of catecholamines and adenosine derivatives given into the brain of fowls. Br J Pharmacol 46:619-636
28. Smith JV, Burdick AJ, Golik P et al (2002) Anti-apoptotic properties of Ginkgo biloba extract EGb 761 in differentiated PC12 cells. Cell Mol Biol (Noisy-le-grand) 48:699-707
29. Smith JV, Luo Y (2004) Studies on molecular mechanisms of Ginkgo biloba extract. Appl Microbiol Biotechnol 64:465-472
30. Birks J, Grimley Evans J (2009) Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev CD003120
31. Wilens TE, Adler LA, Adams J et al (2008) Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry 47:21-31
32. Huss M, Hölling H, Kurth BM, Schlack R (2008) How often are German children and adolescents diagnosed with ADHD? Prevalence based on the judgment of health care professionals: results of the German health and examination survey (KiGGS). Eur Child Adolesc Psychiatry 17(Suppl 1):52-58
33. Schlack R, Hölling H, Kurth BM, Huss M (2007) The prevalence of attention-deficit/hyperactivity disorder (ADHD) among children and adolescents in Germany. Initial results from the German Health Interview and Examination Survey for Children and Adolescents (KiGGS). Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 50:827-835
34. Galert T, Bublitz CH, Heuser I et al (2009) Das optimierte Gehirn. Gehirn Geist 11:1-12
35. Greely H, Sahakian B, Harris J et al (2008) Towards responsible use of cognitive-enhancing drugs by the healthy. Nature 456:702-705
36. Synofzik M (2006) Kognition a la carte? Der Wunsch nach kognitionsverbessernden Psychopharmaka in der Medizin. Z Ethik Med 18:37-50
37. Synofzik M (2009) Ethically justified, clinically applicable criteria for physician decision-making in psychopharmacological enhancement. Neuroethics 2:89-102
38. Jongh R de, Bolt I, Schermer M, Olivier B (2008) Botox for the brain: enhancement of cognition, mood and pro-social behavior and blunting of unwanted memories. Neurosci Biobehav Rev 32:760-776
39. Kandel E, Schwartz JH, Jessel TM (1995) Neurowissenschaften. Eine Einführung. Spektrum, Heidelberg
40. Kandel E (2007) Auf der Suche nach dem Gedächtnis: Die Entstehung einer neuen Wissenschaft des Geistes. Siedler, München
41. Normann C, Boldt J, Maio G, Berger M (2010) Options, limits and ethics of pharmacological neuroenhancement. Nervenarzt 81:66-74
42. Schöne-Seifert B (2008) Enhancement. Die ethische Debatte. Mentis, Paderborn
43. Schöne-Seifert B, Ach JS, Opolka U, Talbot D (2010) Neuro-Enhancement. Ethik vor neuen Herausforderungen. Mentis, Paderborn